Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLAGYL I.V. RTU IN PLASTIC CONTAINER vs ALCAINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metronidazole, a nitroimidazole, exerts bactericidal and antiprotozoal activity via reduction of its nitro group by bacterial or protozoal nitroreductases, forming toxic intermediates that disrupt DNA helical structure and inhibit nucleic acid synthesis.
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.
Treatment of anaerobic bacterial infections (intra-abdominal, skin and skin structure, gynecologic, bone and joint, central nervous system, lower respiratory tract, endocarditis),Treatment of trichomoniasis (symptomatic and asymptomatic),Treatment of bacterial vaginosis,Treatment of amebiasis (intestinal and hepatic),Prophylaxis of postoperative infection in contaminated or potentially contaminated colorectal surgery,Off-label: Management of Clostridium difficile infection, Helicobacter pylori eradication (part of combination therapy), Crohn's disease (perianal fistulas), rosacea (topical)
Ophthalmic anesthesia for procedures such as cataract extraction, tonometry, gonioscopy, and suture removal
Metronidazole: Initial loading dose of 15 mg/kg IV, followed by 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.
1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.
8 hours (6-10 hours) in adults with normal renal function; prolonged to 12-24 hours in severe hepatic impairment.
Terminal elimination half-life: 0.4–1.2 minutes (rapid enzymatic hydrolysis by plasma esterases); clinical significance: ultra-short duration limits systemic toxicity.
Hepatic metabolism via oxidation and glucuronidation; major metabolites include hydroxy-metronidazole (active) and acid metabolites. Enzymes: CYP450 (primarily CYP2A6 and CYP3A4).
Hydrolyzed by plasma esterases.
Renal (60-80% as unchanged drug and metabolites), fecal (6-15%), biliary (minor).
Renal excretion of parent drug and metabolites: <5% unchanged.
<20%, primarily to albumin.
Minimal; <5% bound to plasma proteins.
0.8-1.2 L/kg; indicates extensive tissue penetration including CNS, bone, and abscesses.
Not clinically meaningful due to rapid hydrolysis; Vd estimated <0.5 L/kg (low, consistent with high water solubility and rapid clearance).
Oral: 100% (nearly complete absorption).
Ophthalmic topical: negligible systemic absorption (minimal bioavailability); not applicable systemically.
No adjustment required for GFR >10 m L/min. For GFR <10 m L/min: administer every 12 hours. Hemodialysis: administer normal dose after dialysis; no supplemental dose needed. Peritoneal dialysis: administer normal dose every 12 hours.
No dose adjustment required; negligible systemic absorption.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (e.g., 7.5 mg/kg every 12 hours). Child-Pugh C: use contraindicated or reduce dose to 7.5 mg/kg every 24 hours with close monitoring.
No dose adjustment required; negligible systemic absorption.
Neonates (0-6 weeks): 15 mg/kg IV loading, then 7.5 mg/kg IV every 12 hours. Infants/children (>6 weeks): 15 mg/kg IV loading, then 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.
1 drop of 0.5% solution topically to the eye, repeated as needed; maximum 1 drop per dose in infants and young children to avoid systemic effects.
No specific dose adjustment based solely on age. Monitor renal function and adjust if GFR <10 m L/min. Consider reduced hepatic clearance; use lowest effective dose and monitor for adverse effects.
No specific adjustment; use lowest effective dose due to potential increased corneal sensitivity and delayed healing.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Its use should be reserved for conditions described in the indications. Unnecessary use should be avoided.
Not for injection or prolonged use; corneal toxicity with repeated or prolonged use.
Carcinogenicity risk (animal data; avoid unnecessary use),Seizures and peripheral neuropathy (discontinue if abnormal neurologic signs occur),Hepatic impairment: dose adjustment may be required; caution in severe liver disease,Renal impairment: accumulation of metabolites; monitor for toxicity,Blood dyscrasias: history of or current; monitor CBC with prolonged therapy,Candidiasis: may cause overgrowth; treat appropriately,Disulfiram-like reaction with alcohol: avoid alcohol during and for 48 hours after therapy,Drug interactions: warfarin (increased INR), lithium (increased toxicity), CYP450 inducers/inhibitors,Pregnancy: reserve for serious infections; use in trichomoniasis only if no alternative,Lactation: discontinue breastfeeding or drug, considering importance to mother
Prolonged use may cause corneal epithelial damage and delay wound healing. Avoid contamination of the dropper tip.
Hypersensitivity to metronidazole or other nitroimidazoles,First trimester of pregnancy (for trichomoniasis; relative contraindication),Concurrent use of disulfiram (psychotic reactions possible),Patients with Cockayne syndrome (risk of severe hepatic adverse reactions)
Hypersensitivity to any component of the formulation.
No direct food interactions, but alcohol and alcohol-containing foods (e.g., sauces, vinegar, fermented products) must be strictly avoided during therapy and for 48 hours after completion due to risk of disulfiram-like reaction.
None known.
Metronidazole crosses the placenta. First trimester: Avoid use; data suggest possible teratogenic risk (cleft palate), though not conclusively. Second and third trimesters: Generally considered safe for short-term treatment of bacterial vaginosis or trichomoniasis; no evidence of increased major malformations. However, use only if clearly needed.
Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenic effects at doses up to 0.5 mg/kg (SC). Potential fetal risk unlikely to exceed background risk. No known trimester-specific risks.
Metronidazole is excreted into breast milk with an M/P ratio of approximately 0.9. Infant serum levels may be up to 20% of maternal levels. Due to potential carcinogenicity in animal studies and concerns for infant gastrointestinal effects, the manufacturer recommends discontinuing breastfeeding during therapy and for 24-48 hours after last dose. Alternative washing and pumping may be considered.
Proparacaine is excreted into breast milk in unknown amounts, but due to minimal systemic absorption, the expected dose to infant is negligible. Manufacturer advises caution. No M/P ratio available.
Pregnancy may alter metronidazole pharmacokinetics: slightly increased clearance and volume of distribution. No specific dose adjustment is recommended; use standard dosing (e.g., 500 mg IV every 6-8 hours for anaerobic infections). Avoid high doses and prolonged therapy unless essential.
No dosing adjustment required for topical ophthalmic use due to negligible systemic absorption and lack of pharmacokinetic alterations in pregnancy.
Flagyl IV RTU (metronidazole) is a nitroimidazole antibiotic used for anaerobic infections and protozoal diseases. Avoid alcohol during therapy and for 48 hours after due to disulfiram-like reaction. Infuse slowly over 30-60 minutes to minimize infusion reactions. Monitor for peripheral neuropathy and CNS effects with prolonged use. Use with caution in hepatic impairment; adjust dose in severe liver disease. May cause metallic taste. Do not mix with other drugs in the same IV line. Contraindicated in first trimester of pregnancy unless life-threatening.
ALCAINE (proparacaine) is a topical ophthalmic anesthetic. Onset within 20 seconds, duration ~15 minutes. Do not dispense for home use due to risk of corneal toxicity with prolonged use. Use a sterile, single-dose vial to prevent contamination. Monitor for stinging or burning on instillation. Avoid in patients with sulfite allergy (contains sodium bisulfite).
Do not drink alcohol or use products containing alcohol during treatment and for at least 48 hours after the last dose; this can cause severe nausea, vomiting, flushing, and headache.,This medication may cause a metallic taste in the mouth, which is temporary.,If you experience numbness, tingling, or pain in your hands or feet, or any signs of an allergic reaction, contact your healthcare provider immediately.,For IV administration, the infusion site should be monitored for signs of redness, swelling, or pain.,Take the medication exactly as prescribed; do not stop without consulting your doctor.,Inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
Temporary stinging or burning may occur upon application.,Do not touch the dropper tip to any surface to avoid contamination.,Do not use for more than instructed; prolonged use can damage the cornea.,Remove contact lenses before use and wait at least 15 minutes before reinserting.,Notify your doctor if you have a sulfite allergy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLAGYL I.V. RTU IN PLASTIC CONTAINER vs ALCAINE, answered by our medical review team.
FLAGYL I.V. RTU IN PLASTIC CONTAINER is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole, exerts bactericidal and antiprotozoal activity via reduction of its nitro group by bacterial or protozoal nitroreductases, forming toxic intermediates that disrupt DNA helical structure and inhibit nucleic acid synthesis.. ALCAINE is a Local Anesthetic that works by Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLAGYL I.V. RTU IN PLASTIC CONTAINER and ALCAINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLAGYL I.V. RTU IN PLASTIC CONTAINER is: Metronidazole: Initial loading dose of 15 mg/kg IV, followed by 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.. The standard adult dose of ALCAINE is: 1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLAGYL I.V. RTU IN PLASTIC CONTAINER and ALCAINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLAGYL I.V. RTU IN PLASTIC CONTAINER is classified as Category C. Metronidazole crosses the placenta. First trimester: Avoid use; data suggest possible teratogenic risk (cleft palate), though not conclusively. Second and third trimesters: General. ALCAINE is classified as Category C. Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant wom. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.